Active Filter(s):
Details:
TLL-018 is a novel, highly potent, and selective TYK2/JAK1 inhibitor. TYK2 and JAK1 are the key regulators of pro-inflammatory cytokines. It is being investigated for the treatment of plaque psoriasis.
Lead Product(s): TLL-018
Therapeutic Area: Dermatology Product Name: TLL-018
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023